Crossmark

The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan)

Crossref DOI link: https://doi.org/10.1038/s41598-025-93136-9

Published Online: 2025-04-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shiota, Masaki

Liu, Yanfang

Mundle, Suneel

Nematian-Samani, Mehregan

Hwang, Jason

Wang, Xiayi

Uemura, Hirotsugu
License Information

Text and Data Mining valid from 2025-04-19

Version of Record valid from 2025-04-19
More Information

Article History

Received: 26 June 2024

Accepted: 5 March 2025

First Online: 19 April 2025

Declarations

:

: Masaki Shiota has received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi and Bayer Yakuhin, and research funding support from Astellas Pharma. Yanfang Liu, Suneel Mundle, Xiayi Wang, Mehregan Nematian-Samani, and Jason Hwang are employees of Johnson & Johnson LLC. Yanfang Liu, Suneel Mundle hold stock/shares in Johnson & Johnson Pte, Ltd. Hirotsugu Uemura reports grants and other from Takeda, Ono pharm. Astellas, Janssen, Astra Zeneca, personal fees from Bayer, MSD, BMS, Janssen, Takeda, Pfizer, Sanofi, Eisai, and Ono/BMS outside the submitted work.

Document is current

Any future updates will be listed below